Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc (LSE/NYSE: HLN) covers the month of May 2025, specifically dated May 2, 2025. The report serves as a notification of transactions by Persons Discharging Managerial Responsibilities (PDMRs) in accordance with the UK Market Abuse Regulation. Haleon operates as a global leader in consumer health with a portfolio spanning oral health, vitamins, pain relief, respiratory health, digestive health, and therapeutic skin health.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider trading activity rather than a financial results report.
Material Changes
The material change disclosed is a transaction by an Independent Non-Executive Director. Asmita Dubey purchased 15,424 ordinary shares of Haleon Plc at a price of £4.01 per share on May 2, 2025, on the London Stock Exchange. No other material changes to the company's operations or financial position are detailed in this filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is strictly limited to the disclosure of the PDMR share purchase.
Key Facts for Investor Verification
- Transaction Type: Purchase of Ordinary Shares by an Independent Non-Executive Director.
- Individual: Asmita Dubey.
- Volume and Price: 15,424 shares purchased at £4.01 per share.
- Date and Venue: May 2, 2025, on the London Stock Exchange (XLON).
- Regulatory Basis: Disclosure required under the UK Market Abuse Regulation.